JCR Pharmaceuticals is a Japanese specialty biopharmaceutical firm focused on developing and manufacturing innovative therapies for rare and genetic diseases.

Founded in 1975 and headquartered in Ashiya, Hyōgo Prefecture, Japan, JCR Pharmaceuticals Co., Ltd. has grown from a domestic pharmaceutical manufacturer into a global biotech company with subsidiaries in the United States, Europe and Brazil. The company specialises in research, development, manufacturing and sales of therapies for rare and complex diseases, leveraging proprietary technologies such as J‑Brain Cargo®, a platform that enables delivery of biologics across the blood–brain barrier. JCR combines a strong R&D focus with integrated biomanufacturing capabilities to support both its internal pipeline and external partnerships .

Key Products and Services

TEMCELL® HS Inj. – Japan’s first approved allogeneic regenerative medicine product for treating acute graft‑versus‑host disease, approved in 2015.

IZCARGO® (pabinafusp alfa) – A fusion protein treatment for mucopolysaccharidosis II (Hunter syndrome), employing J‑Brain Cargo® technology, approved in Japan in 2021.

GROWJECT® – A recombinant human growth hormone injection for growth hormone deficiency, first approved in Japan in 1993.

Agalsidase Beta BS I.V. Infusion – A treatment for Fabry disease launched in Japan in 2018.

Epoetin Alfa BS and Darbepoetin Alfa BS injections – Therapies for renal anaemia, approved in Japan in 2010 and 2019, respectively.

Pipeline products – Includes JR‑141 (for MPS II), JR‑171 (MPS I), JR‑441 (MPS IIIA), JR‑446 (MPS IIIB), and others, driven by CNS‑penetrating technology.

Contract Development & Manufacturing (CDMO) – Provision of regenerative medicine, cell and gene therapy manufacturing services, including recent government-supported CDMO expansion.

AlliedCel joint venture – A 50:50 partnership with Sysmex established in October 2022 to advance research, manufacturing and commercialisation of regenerative medicine and cell therapy products.

JCR Pharmaceuticals continues to build on its half‑century heritage in rare disease treatment and regenerative medicine. With proprietary technologies, a robust global R&D pipeline, and expanding biomanufacturing and CDMO capabilities, the company is advancing its mission to deliver next‑generation therapies for underserved patient populations worldwide.